Sovaldi

Generic name: Sofosbuvir
Drug class: Miscellaneous antivirals

Usage of Sovaldi

Sovaldi is an antiviral medication that prevents hepatitis C virus (HCV) from multiplying in your body.

Sovaldi is used to treat chronic hepatitis C in adults and children who are at least 3 years old.

Sovaldi must be given in combination with other antiviral medications (usually ribavirin with or without peginterferon alfa). It should not be used alone.

Sovaldi treats specific genotypes of hepatitis C, and only in certain people. Use only the medications prescribed for you. Do not share your medicine with other people.

Sovaldi is sometimes used in people who also have HIV, or people who have liver cancer and are going to have a liver transplant. This medicine is not a treatment for HIV or AIDS.

Sovaldi side effects

Get emergency medical help if you have signs of an allergic reaction to Sovaldi: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have new or worsening symptoms such as:

right-sided upper stomach pain, vomiting, loss of appetite;

dark urine, clay-colored stools; or

jaundice (yellowing of the skin or eyes).

If you take Sovaldi and you also take a heart rhythm medicine called amiodarone: This combination of medicines can cause dangerous side effects on your heart. Get medical help right away if you take these medicines and you have:

very slow heartbeats, chest pain, shortness of breath;

confusion, memory problems; or

weakness, extreme tiredness, light-headed feeling (like you might pass out).

Common Sovaldi side effects may include:

headache, feeling tired;

anemia;

nausea, loss of appetite; or

sleep problems (insomnia).

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Before taking Sovaldi

You should not use Sovaldi if you are allergic to sofosbuvir. When taking Sovaldi with other medicine: To make sure all medicines are safe for you, tell your doctor about all your medical conditions, and if you are pregnant or breastfeeding.

To make sure Sovaldi is safe for you, tell your doctor if you have ever had:

hepatitis B (you may be tested for this before you take sofosbuvir);

a liver transplant;

liver problems other than hepatitis C;

kidney disease (or if you are on dialysis);

HIV or AIDS;

a heart rhythm problem for which you take a medicine called amiodarone; or

if you use a blood thinner (warfarin, Coumadin, Jantoven) and you have routine "INR" or prothrombin time tests.

Sovaldi is sometimes used in combination with ribavirin. Both men and women using ribavirin should use effective birth control to prevent pregnancy. Ribavirin can cause birth defects, miscarriage, or death to an unborn baby if the mother or father is using this medicine.

You should not take ribavirin if you are pregnant, or if you are a man and your sex partner is pregnant. Use effective birth control to prevent pregnancy. Keep using birth control for at least 6 months after your last dose of ribavirin.

Tell your doctor right away if a pregnancy occurs while either the mother or the father is using ribavirin.

It may not be safe to breastfeed while using Sovaldi. Ask your doctor about any risk.

Sovaldi is not approved for use by anyone younger than 3 years old.

Relate drugs

How to use Sovaldi

Usual Adult Dose for Chronic Hepatitis C:

400 mg orally once a day Recommended Regimen and Duration of Therapy: -Genotype 1 or 4: Sofosbuvir, peginterferon alfa, and ribavirin for 12 weeks -Genotype 2: Sofosbuvir and ribavirin for 12 weeks -Genotype 3: Sofosbuvir and ribavirin for 24 weeks -Hepatocellular carcinoma awaiting liver transplantation: Sofosbuvir and ribavirin for up to 48 weeks or until liver transplantation (whichever occurs first) Comments: -Genotype 1, 4: This regimen is recommended for therapy-naive patients without cirrhosis or with compensated cirrhosis (Child-Pugh A). -Genotype 2, 3: Both regimens are recommended for therapy-naive and therapy-experienced patients without cirrhosis or with compensated cirrhosis (Child-Pugh A). -Therapy-experienced patients have failed an interferon-based regimen (with or without ribavirin). -The dose recommendations for genotype 1, 2, 3, or 4 should be followed for HCV/HIV-1-coinfected patients. -The manufacturer product information should be consulted for ribavirin tablet dose recommendations; with genotype 1 or 4, the manufacturer product information for peginterferon alfa should also be consulted for dose recommendations. -Sofosbuvir and ribavirin for 24 weeks can be considered for patients with genotype 1 infection who cannot use an interferon-based regimen; treatment decision should be guided by benefit/risk assessment for the individual patient. -The regimen for patients with hepatocellular carcinoma awaiting liver transplantation is recommended to prevent posttransplant HCV reinfection. Use: As a part of a combination antiviral treatment regimen, for the treatment of chronic HCV infection -In combination with pegylated interferon and ribavirin: For genotype 1 or 4 infection without cirrhosis or with compensated cirrhosis -In combination with ribavirin: For genotype 2 or 3 infection without cirrhosis or with compensated cirrhosis

Usual Pediatric Dose for Chronic Hepatitis C:

3 years or older: -Weight less than 17 kg: 150 mg orally once a day -Weight 17 to less than 35 kg: 200 mg orally once a day -Weight at least 35 kg: 400 mg orally once a day Recommended Regimen and Duration of Therapy: -Genotype 2: Sofosbuvir and ribavirin for 12 weeks -Genotype 3: Sofosbuvir and ribavirin for 24 weeks -Hepatocellular carcinoma awaiting liver transplantation: Sofosbuvir and ribavirin for up to 48 weeks or until liver transplantation (whichever occurs first) Comments: -Both regimens are recommended for therapy-naive and therapy-experienced patients without cirrhosis or with compensated cirrhosis (Child-Pugh A). -Therapy-experienced patients have failed an interferon-based regimen (with or without ribavirin). -The manufacturer product information should be consulted for ribavirin dose recommendations. -The same dose recommendations should be followed for HCV/HIV-1-coinfected patients. -The regimen for patients with hepatocellular carcinoma awaiting liver transplantation is recommended to prevent posttransplant HCV reinfection. Use: In combination with ribavirin, for the treatment of chronic HCV genotype 2 or 3 infection in patients without cirrhosis or with compensated cirrhosis

Warnings

If you've ever had hepatitis B, it may become active or get worse while using or after you stop using Sovaldi. You may need frequent liver function tests for several months.

Sovaldi is used in combination with other medication. Read the medication guide or patient instructions provided with each medication in your combination therapy. Do not change your doses or medication schedule without your doctor's advice.

Sovaldi can cause birth defects or death in an unborn baby. Do not use Sovaldi with ribavirin if you are pregnant, or if you are a man and your female sexual partner is pregnant. Use at least 2 effective forms of non-hormonal birth control while using these medicines together and for at least 6 months after treatment ends.

What other drugs will affect Sovaldi

When you start or stop taking Sovaldi, your doctor may need to adjust the doses of any other medicines you take on a regular basis.

Sometimes it is not safe to use certain medications at the same time. Some drugs can affect your blood levels of other drugs you take, which may increase side effects or make the medications less effective.

Many drugs can interact with sofosbuvir. This includes prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible interactions are listed here. Tell your doctor about all your current medicines and any medicine you start or stop using.

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.